tradingkey.logo

Trinity Biotech PLC

TRIB
0.990USD
+0.004+0.44%
Market hours ETQuotes delayed by 15 min
8.21MMarket Cap
LossP/E TTM

Trinity Biotech PLC

0.990
+0.004+0.44%

More Details of Trinity Biotech PLC Company

Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.

Trinity Biotech PLC Info

Ticker SymbolTRIB
Company nameTrinity Biotech PLC
IPO dateOct 21, 1992
CEOMr. John Gillard
Number of employees- -
Security typeDepository Receipt
Fiscal year-endOct 21
AddressIda Business Park, Bray, Co Wicklow
CityDUBLIN
Stock exchangeNASDAQ Global Select Consolidated
CountryIreland
Postal code18
Phone01135312955111
Websitehttps://www.trinitybiotech.com/
Ticker SymbolTRIB
IPO dateOct 21, 1992
CEOMr. John Gillard

Company Executives of Trinity Biotech PLC

Name
Name/Position
Position
Shareholding
Change
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
By RegionUSD
Name
Revenue
Proportion
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

Shareholding Stats

Updated: Thu, Oct 23
Updated: Thu, Oct 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
48.04%
Hunter Associates Investment Management LLC
2.61%
MiCo IVD Holdings, LLC
2.40%
Moss Adams Wealth Advisors LLC
0.14%
Whitefort Capital Management, LP
0.09%
Other
46.72%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
48.04%
Hunter Associates Investment Management LLC
2.61%
MiCo IVD Holdings, LLC
2.40%
Moss Adams Wealth Advisors LLC
0.14%
Whitefort Capital Management, LP
0.09%
Other
46.72%
Shareholder Types
Shareholders
Proportion
Private Equity
48.04%
Investment Advisor
3.00%
Corporation
2.40%
Hedge Fund
0.17%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.03%
Venture Capital
0.03%
Other
46.29%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
51
972.44K
12.90%
+718.78K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
2023Q2
47
3.98M
52.08%
+190.03K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
358.00K
1.92%
+358.00K
--
Jun 30, 2025
Hunter Associates Investment Management LLC
87.58K
0.47%
+12.56K
+16.74%
Jun 30, 2025
MiCo IVD Holdings, LLC
447.59K
2.4%
--
--
Dec 17, 2024
Moss Adams Wealth Advisors LLC
5.13K
0.03%
--
--
Jun 30, 2025
Whitefort Capital Management, LP
16.38K
0.09%
--
--
Jun 30, 2025
Williams & Novak Wealth Management, LLC
4.40K
0.02%
+760.00
+20.88%
Jun 30, 2025
Renaissance Technologies LLC
11.39K
0.06%
-3.94K
-25.70%
Jun 30, 2025
Inspirion Wealth Advisors, LLC
10.00K
0.05%
+8.00K
+400.00%
Sep 30, 2025
Highbridge Capital Management, LLC
6.75K
0.04%
+6.75K
--
Mar 31, 2024
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Date
Type
Ratio
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
KeyAI